Celyad Oncology SA American Depositary Shares
CYAD
CYAD was delisted on the 18th of May, 2023.
4 hedge funds and large institutions have $16M invested in Celyad Oncology SA American Depositary Shares in 2017 Q2 according to their latest regulatory filings, with funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.
53% more capital invested
Capital invested by funds: $10.5M → $16M (+$5.54M)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
33% less funds holding
Funds holding: 6 → 4 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$33.5K |
| 2 |
Morgan Stanley
New York
|
+$15.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$328K |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$75.3K |
| 3 |
Zurich Cantonal Bank
Zurich,
Switzerland
|
-$42K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$13.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Victory Capital Management
San Antonio,
Texas
| $15.8M | -$75.3K | -1,901 | -0.5% |
|
|
2
Morgan Stanley
New York
| $150K | +$15.8K | +400 | +13% |
|
|
3
UBS Group
Zurich,
Switzerland
| $53K | +$33.5K | +846 | +206% |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $1K | -$13.3K | -337 | -94% |
|
|
DCM
5
DAFNA Capital Management
Los Angeles,
California
| – | -$328K | -12,528 | Closed |
|
|
6
Zurich Cantonal Bank
Zurich,
Switzerland
| – | -$42K | -1,560 | Closed |
|
CYAD Hedge Fund Activity: Q2 2017 in Review
4 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Celyad Oncology SA American Depositary Shares (CYAD) for Q2 2017, worth a combined $16M — up 53% from $10.5M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of CYAD and 0 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 2 added.
The largest buyer was UBS Group, adding an estimated $33.5K. The largest seller was DAFNA Capital Management, exiting entirely with an estimated $328K sold.
- 4 institutional investors held Celyad Oncology SA American Depositary Shares (CYAD) as of Q2 2017, down from 6 in Q1 2017.
- Funds reported $16M of Celyad Oncology SA American Depositary Shares stock for Q2 2017, up 53% quarter-over-quarter.
- 0 funds opened new Celyad Oncology SA American Depositary Shares positions in Q2 2017 and 2 closed out, a net change of -2 holders.
- The largest Celyad Oncology SA American Depositary Shares buyer in Q2 2017 was UBS Group, an estimated $33.5K added.
- The largest Celyad Oncology SA American Depositary Shares seller in Q2 2017 was DAFNA Capital Management, an estimated $328K sold.
Based on aggregated 13F filings for Q2 2017.